Everist Genomics to Open New Laboratory in San Diego
SAN DIEGO, CA & ANN ARBOR, MI, July 10, 2012 – Everist Genomics (EGI), a privately held personalized medicine company developing innovative diagnostics for oncology and cardiovascular disease, announced today that it will open a new satellite lab in San Diego in Q3 2012.
“In the biotechnology sector, San Diego is seen as one of the world’s biggest hotbeds of innovation,” said Alex Charlton, Executive Vice Chairman of EGI. “The expansion of EGI into the area represents an exciting opportunity for us to showcase the unique capabilities of our diagnostics, prognostics and therapeutic selection technologies, which are underpinned by the company’s strong IP position. Ultimately, we expect this expansion to support our entire business strategy, from new product development to marketing and sales, catalyzing both short-term and long-term growth opportunities.”
By locating the company’s new lab in one of the world’s top global biotechnology hubs, EGI can evaluate opportunities for partnerships with other life science companies. EGI also sees tremendous added value by having close proximity to Silicon Valley.
EGI has already begun marketing a number of products in areas such as colorectal cancer and cardiovascular disease through its ongoing R&D programs and industry partnerships. The company launched its first companion diagnostic test, OncoDefender-CRC, in June 2011 and has already distributed more than 6,000 OncoDefender-CRC test kits to hospitals around the country. In March 2012, the company expanded its companion diagnostics portfolio and began marketing three new tests — OncoSelector, OncoDefender-MMR and OncoDefender-Lynch Syndrome. Through several strategic product acquisitions, the company has also entered the cardiovascular space, launching two new mobile health diagnostics, CardioDefender and AngioDefender. These devices integrate novel sensor technology with mobile digital services, smartphones and other mobile devices to provide flexible monitoring and diagnosis of cardiovascular conditions that traditionally have been limited to observation through legacy hospital diagnostic systems.
At the company’s new laboratory in San Diego, EGI will focus on continuing to build out its colorectal cancer and cardiovascular disease portfolios, leveraging its proprietary machine learning algorithm, Evolver, to identify and assess new biomarkers that are relevant to disease prognosis and treatment. EGI is also exploring new technologies and platforms designed to advance treatment planning in other indications, such as metabolic disease
Everist Genomics’ new operations will be located in Janssen Labs at Janssen Research & Development, LLC in San Diego, CA. Janssen Labs is a 30,000-square-foot life science innovation center, located within the Janssen Research & Development, LLC’s West Coast Research Center. The labs provide a flexible lab environment for start-up companies pursuing new technologies and research platforms to advance medical care.
About Everist Genomics
Everist Genomics, Inc. (EGI) is a personalized medicine company, which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. EGI is focused on rapidly growing disease areas with major unmet needs, including cancer, cardiovascular disease and metabolic disease (e.g. diabetes). EGI’s innovative products successfully integrate with mobile digital services, smartphones and tablet computers resulting in advanced medical technology, which until now has been confined to the hospital setting. For online information about Everist Genomics, please visit www.everistgenomics.com.